Use of COLD-fX to Prevent Respiratory Infections in Community Dwelling Seniors
Efficacy and Safety of COLD-fX in the Prevention of Respiratory Infections in Community-dwelling Seniors: a Multi-center, Randomized, Double-blind, Placebo-controlled Trial
Sponsor: Afexa Life Sciences Inc
Listed as NCT00240461, this PHASE3 trial focuses on Respiratory Tract Infection and remains completed. Sponsored by Afexa Life Sciences Inc, it has been updated 5 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Sep 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Afexa Life Sciences Inc
- Capital Health, Canada
- Erasmus Medical Center
- IWK Health Centre
- Sunnybrook Health Sciences Centre
- University of BC Gerontology & Diabetes Research
For direct contact, visit the study record on ClinicalTrials.gov .